glp-1 agonist drug interactions and Telehealth Weight Loss Care The current significance and prospects

doi: 10.1016/S2213-2600(19)30198-5, 2

Sources of uncertainty originate from the panoply of glycemic targets, the complexity of drug therapy, the choice of the first drug, the ideal sequence of drugs after the first drug failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat for preventing the vascular complications

DPP-4 inhibitors are body weight neutral and they are generally tolerated well without side effects (see also corresponding section below) (12, 19, 21, 22)

The release of proglucagon causes the liver to make glucose (gluconeogenesis converting protein to glucose) as well as to convert fatty acids into ketone bodies

Universitt Tbingen